|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar
|
|
3
|
Saintigny P and Burger JA: Recent advances
in non-small cell lung cancer biology and clinical management.
Discov Med. 13:287–297. 2012.PubMed/NCBI
|
|
4
|
Dy GK and Adjei AA: Emerging therapeutic
targets in non-small cell lung cancer. Proc Am Thorac Soc.
6:218–223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ciechanover A and Iwai K: The ubiquitin
system: From basic mechanisms to the patient bed. IUBMB life.
56:193–201. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakayama KI and Nakayama K: Ubiquitin
ligases: Cell-cycle control and cancer. Nat Rev Cancer. 6:369–381.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pal A, Young MA and Donato NJ: Emerging
potential of therapeutic targeting of ubiquitin-specific proteases
in the treatment of cancer. Cancer Res. 74:4955–4966. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shen M, Schmitt S, Buac D and Dou QP:
Targeting the ubiq-uitin-proteasome system for cancer therapy.
Expert Opin Ther Targets. 17:1091–1108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duncan SJ, Cooper MA and Williams DH:
Binding of an inhibitor of the p53/MDM2 interaction to MDM2. Chem
Commun. 7:316–317. 2003. View
Article : Google Scholar
|
|
11
|
Yokoi S, Yasui K, Mori M, Iizasa T,
Fujisawa T and Inazawa J: Amplification and overexpression of SKP2
are associated with metastasis of non-small-cell lung cancers to
lymph nodes. Am J Pathol. 165:175–180. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang F, Caraway NP, Li R and Katz RL: RNA
silencing of S-phase kinase-interacting protein 2 inhibits
proliferation and centrosome amplification in lung cancer cells.
Oncogene. 24:3409–3418. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fujita Y, Krause G, Scheffner M, Zechner
D, Leddy HE, Behrens J, Sommer T and Birchmeier W: Hakai, a
c-Cbl-like protein, ubiquitinates and induces endocytosis of the
E-cadherin complex. Nat Cell Biol. 4:222–231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rodríguez-Rigueiro T, Valladares-Ayerbes
M, Haz-Conde M, Aparicio LA and Figueroa A: Hakai reduces
cell-substratum adhesion and increases epithelial cell invasion.
BMC Cancer. 11:4742011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Figueroa A, Fujita Y and Gorospe M:
Hacking RNA: Hakai promotes tumorigenesis by enhancing the
RNA-binding function of PSF. Cell Cycle. 8:3648–3651. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Figueroa A, Kotani H, Toda Y,
Mazan-Mamczarz K, Mueller EC, Otto A, Disch L, Norman M, Ramdasi
RM, Keshtgar M, et al: Novel roles of hakai in cell proliferation
and oncogenesis. Mol Biol Cell. 20:3533–3542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deep G, Gangar SC, Agarwal C and Agarwal
R: Role of E-cadherin in antimigratory and antiinvasive efficacy of
silibinin in prostate cancer cells. Cancer Prev Res. 4:1222–1232.
2011. View Article : Google Scholar
|
|
18
|
Aparicio LA, Castosa R, Haz-Conde M,
Rodríguez M, Blanco M, Valladares M and Figueroa A: Role of the
microtubule-targeting drug vinflunine on cell-cell adhesions in
bladder epithelial tumour cells. BMC cancer. 14:5072014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ,
Liu YQ, Pu JX, Xiao WL, Sun HD and Zhou GB: Overexpression and
small molecule-triggered downregulation of CIP2A in lung cancer.
PLoS One. 6:e201592011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Testa JR and Bellacosa A: AKT plays a
central role in tumorigenesis. Proc Natl Acad Sci USA.
98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
22
|
Tang JM, He QY, Guo RX and Chang XJ:
Phosphorylated Akt overexpression and loss of PTEN expression in
non-small cell lung cancer confers poor prognosis. Lung Cancer.
51:181–191. 2006. View Article : Google Scholar
|
|
23
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmidt LH, Spieker T, Koschmieder S,
Schäffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D,
Marra A, et al: The long noncoding MALAT-1 RNA indicates a poor
prognosis in non-small cell lung cancer and induces migration and
tumor growth. J Thorac Oncol. 6:1984–1992. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu D, Huang C, Kameyama K, Hayashi E,
Yamauchi A, Kobayashi S and Yokomise H: E-cadherin expression
associated with differentiation and prognosis in patients with
non-small cell lung cancer. Ann Thorac Surg. 71:949–954. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bremnes RM, Veve R, Gabrielson E, Hirsch
FR, Baron A, Bemis L, Gemmill RM, Drabkin HA and Franklin WA:
High-throughput tissue microarray analysis used to evaluate biology
and prognostic significance of the E-cadherin pathway in
non-small-cell lung cancer. J Clin Oncol. 20:2417–2428. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soltermann A: Epithelial-mesenchymal
transition in non-small cell lung cancer. Der Pathologe. 33(Suppl
2): S311–S317. 2012.In German. View Article : Google Scholar
|
|
29
|
Kurie JM: Role of protein kinase
B-dependent signaling in lung tumorigenesis. Chest. 125(Suppl):
S141–S144. 2004. View Article : Google Scholar
|
|
30
|
Scrima M, De Marco C, Fabiani F, Franco R,
Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, et
al: Signaling networks associated with AKT activation in non-small
cell lung cancer (NSCLC): New insights on the role of
phosphatydil-inositol-3 kinase. PLoS One. 7:e304272012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang X, Fraser M, Abedini MR, Bai T and
Tsang BK: Regulation of apoptosis-inducing factor-mediated,
cisplatin-induced apoptosis by Akt. Br J Cancer. 98:803–808. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin Y, Wang Z, Liu L and Chen L: Akt is
the downstream target of GRP78 in mediating cisplatin resistance in
ER stress-tolerant human lung cancer cells. Lung Cancer.
71:291–297. 2011. View Article : Google Scholar
|
